Fund Holdings — Kynam Capital Management, LP

Total Portfolio Value
$1.34B
Total Bought
$179.94M
Total Sold
$73.79M
Net Transaction
+$106.14M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q2 2025
▲▼
Q3 2025
▲▼
Change
▲▼
Q2 2025
▲▼
Q3 2025
▲▼
Weight (%)
▲▼
Change
▲▼
COGENT BIOSCIENCES INC(COGT)8,492,5577,886,172-606,38560,977113,2458.43%+52,269
SYNDAX PHARMACEUTICALS INC(SNDX)8,520,0008,520,000079,790131,0809.76%+51,290
VERA THERAPEUTICS INC(VERA)3,426,8874,027,800+600,91380,737117,0488.71%+36,310
MBX BIOSCIENCES INC(MBX)02,000,000+2,000,000035,0002.61%+35,000
CELLDEX THERAPEUTICS INC NEW(CLDX)6,100,7296,100,7290124,150157,82611.75%+33,676
VIRIDIAN THERAPEUTICS INC(VRDN)4,427,9274,427,927061,90295,5557.11%+33,652
UNITED THERAPEUTICS CORP DEL(UTHR)067,588+67,588020,0101.49%+20,010
BEAM THERAPEUTICS INC(BEAM)2,417,6472,517,647+100,00041,12461,1034.55%+19,979
APELLIS PHARMACEUTICALS INC
COM
0808,607+808,607018,2991.36%+18,299
CG ONCOLOGY INC(CGON)2,457,6672,005,205-452,46263,89980,7706.01%+16,870
PHARVARIS N V
COM
0675,000+675,000016,8411.25%+16,841
ENGENE HOLDINGS INC
COM
4,994,0904,994,090018,17834,1102.54%+15,931
VAXCYTE INC(PCVX)3,071,5883,071,588099,857110,6398.24%+10,781
TYRA BIOSCIENCES INC(TYRA)2,329,9982,329,998022,29832,5972.43%+10,299
KALVISTA PHARMACEUTICALS INC0606,171+606,17107,3830.55%+7,383
CYTOMX THERAPEUTICS INC(CTMX)2,154,4133,646,503+1,492,0904,89111,6320.87%+6,742
NURIX THERAPEUTICS INC(NRIX)1,173,6052,168,605+995,00013,36720,0381.49%+6,671
IMMUNOCORE HLDGS PLC(IMCR)976,2671,009,267+33,00030,63536,6672.73%+6,031
BURNING ROCK BIOTECH LTD(BNR)994,883994,88303,1448,6060.64%+5,462
RELAY THERAPEUTICS INC(RLAY)2,887,0142,887,01409,98915,0701.12%+5,081
DESIGN THERAPEUTICS INC(DSGN)1,029,5791,029,57903,4707,7530.58%+4,283
WAVE LIFE SCIENCES LTD(WVE)4,560,0534,560,053029,64033,3802.49%+3,739
CARIBOU BIOSCIENCES INC(CRBU)3,067,7743,067,77403,8657,1480.53%+3,283
IRONWOOD PHARMACEUTICALS INC(IRWD)5,466,8255,466,82503,9217,1620.53%+3,241
CLIMB BIO INC(CLYM)1,028,3411,028,34101,2752,0670.15%+792
EDGEWISE THERAPEUTICS INC(EWTX)253,979253,97903,3304,1200.31%+790
SUTRO BIOPHARMA INC(STRO)5,088,0995,088,09903,6324,4190.33%+786
PROQR THRAPEUTICS N V
SHS EURO
1,649,4621,649,46203,3653,5130.26%+148
AMARIN CORP PLC576,111576,11109,3459,4370.70%+92
DYNAVAX TECHNOLOGIES CORP2,145,3192,145,319021,28221,3031.59%+21
TRAVERE THERAPEUTICS INC(TVTX)1,540,691949,727-590,96422,80222,6981.69%-104
GERON CORP(GERN)3,456,3183,456,31804,8734,7350.35%-138
UROGEN PHARMA LTD(URGN)656,573282,412-374,1618,9956,9360.52%-2,059
CULLINAN THERAPEUTICS INC(CGEM)2,095,9982,302,172+206,17415,75813,6521.02%-2,106
LIQUIDIA CORPORATION(LQDA)200,0470-200,0472,4930—-2,493
BIOCRYST PHARMACEUTICALS INC(BCRX)8,463,7429,390,270+926,52875,83571,2725.31%-4,563
Page 1 of 1
Kynam Capital Management, LP — 13F Holdings — Q3 2025 | TickerTrail